3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
2
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
3
pembrolizumab
2
Magnetic Resonance Spectroscopy
2
Doxorubicin
2
Biopsy
2
talimogene laherparepvec
1
peposertib
1
liposomal doxorubicin
1
fludarabine
1
aldesleukin
1
X-Rays
1
Radiotherapy
1
Radiation
1
Nivolumab
1
Ipilimumab
1
Histamine H2 Antagonists
1
Famotidine
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
Erlotinib Hydrochloride
×
30 days
×
Clear all
No trials found.